StageMark developed an early identification and monitoring solution for inflammatory diseases such as lupus. StageMark's platform CB-CAPs technology — for Cell-Bound Complement Activation Products — was discovered by Dr. Sue Manzi, MD, MPH and Joseph Ahearn, MD, Ph.D., rheumatology clinicians and scientists from the University of Pittsburgh Medical Center (UPMC) Lupus Center of Excellence at Magee Women’s Hospital.